Search results
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
If you are considering employing someone with inherited sight loss, or have an employee recently been diagnosed with the condition, you will need to take steps to ensure that you treat them fairly and that they can work safely and effectively.
Genetic counsellors are specially trained healthcare professionals with extensive scientific knowledge who spend time talking to families living with inherited conditions.
This October, join Retina UK on Halloween weekend (28 and 29 October 2023) and face your fears by taking on a Halloween skydive at various airfields around the UK.
This November, join Retina UK on Bonfire weekend (4 and 5 November 2023) and face your fears by taking on a Bonfire skydive at various airfields around the UK.
